NCT02494986View on ClinicalTrials.gov

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 6, 2015

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Human Immunodeficiency Virus Type 1
Interventions
DRUG

Rilpivirine

Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.

Trial Locations (8)

Unknown

Porto

Bloemfontein

Dundee

Esplugues de Llobregat

Bangkok

Nonthaburi

Entebbe

Kampala

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY